Skip to main content

Rivastigmine News

Novartis Exelon Patch Now FDA Approved to Treat Patients Across all Stages of Alzheimer's Disease

EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ – The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the...

Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease

EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Alzheimer's Disease, Parkinson's Disease

Rivastigmine patient information at Drugs.com